Two Huge Developments


Sheba’s ARC- Accelerates, Redesigns and Collaborates in Canada

ARC Canada was launched by Sheba earlier this month at Ottawa Hospital in the presence of Ottawa Hospital CEO Dr. Jack Kitts and VP for Quality and Innovation Dr. Alan Forster, along with Sheba’s Chief Medical Officer and Chief Innovation Officer Dr. Eyal Zimlichman. 

This is the first ARC Innovation Center site to be established outside of Israel with more sites in the planning stages for leading academic medical centers around the globe. ARC’s strategy accelerates innovative healthcare technologies worldwide.


Forbes Israel Names Talia Golan as One of 50 Most Influential Women in Israel

Forbes Israel’s annual “50 Most Influential Women in Israel” list named Dr. Talia Golan, who heads Sheba’s Pancreatic Cancer Center, as the 27th most influential woman in the country. The prestigious magazine cited Dr. Golan’s headline-making research into a therapeutic regimen known as POLO, which showed promising results in treating deadly pancreatic cancer in patients with the BRCA 1 & 2 mutation.

Dr. Golan has spent the better part of a decade doing research on the impact of this regimen, which uses a new drug from AstraZeneca/Merck known as Lynparza. “My patients always come first. I had known early on that POLO and Lynparza had potential. The results are more than a personal achievement,” said Dr. Golan. “It is privilege to be able to do this research in order to combat this terrible disease and give people real hope for the first time.”